Quintrio
Home

PHARMACEUTICAL PREPARATIONS

ProMIS Neurosciences Inc. Common Shares (ON)

PMN

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Last trade $3.25
Day change -$0.06 (-1.81%)
Day range $3.11 – $3.58
Volume 93,928
Market cap $30M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$29.68M
Price / earnings
—
Price / book
0.71×
Price / sales
—
EV / sales
—
EV / EBITDA
0.36×

Profitability

Earnings per share
-$4.33
Return on assets
-82.29%
Return on equity
-92.93%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.83×
Quick ratio
8.83×
Cash ratio
8.25×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$41.43M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PMN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.91M$2.74M$1.67M$1.4M$1.95M$1.43M$2M$1.68M
Research and development$6.71M$9.52M$6.97M$9.37M$9.8M$8.75M$5.46M$4.32M
Total operating expenses$8.62M$12.27M$8.64M$10.77M$11.75M$10.18M$7.46M$6M
Operating income-$8.62M-$12.27M-$8.64M-$10.77M-$11.75M-$10.18M-$7.46M-$6M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$8.16M-$11.73M-$8.24M-$10.67M-$11.58M-$10.12M-$7.35M-$238.21K
Income taxes$0$0$0$0$0$0$0$0
Net income-$8.16M-$11.73M-$8.24M-$10.67M-$11.58M-$10.12M-$7.35M-$238.21K
Net income attributable to common shareholders-$8.16M-$11.73M-$8.24M-$10.67M-$11.58M-$10.12M-$7.35M-$238.21K
EBITDA-$8.62M-$12.27M-$8.64M-$10.77M-$11.75M-$10.18M-$7.46M-$6M
Basic earnings per share-$0.89-$1.28-$1.26-$4.67-$5.93-$7.26-$5.27-$0.17
Diluted earnings per share-$0.89-$1.28-$1.26-$4.67-$5.93-$7.26-$5.27-$0.16

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline

ProMIS Neurosciences has licensed TXP1, a brain-selective shuttling technology from Ossianix that demonstrated 65-fold increased antibody delivery to the brain in preclinical studies. The technology will be applied to PMN310 (Alzheimer's disease lead candidate) and optionally to the company's Parkinson's disease and ALS programs. The PRECISE-AD Phase 1b trial remains on track for Q1 2027 topline data.

GlobeNewswire Inc.

ProMIS Neurosciences to Participate in Upcoming Conferences in November

ProMIS Neurosciences Inc. announced its participation in multiple healthcare conferences throughout November 2026, including presentations and fireside chats by CEO Neil Warma at venues in Boston, New York, and London. The company will present interim safety and biomarker analysis data from its PRECISE-AD trial at the Clinical Trials on Alzheimer's Disease conference.

GlobeNewswire Inc.

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

GlobeNewswire Inc.

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

ProMIS Neurosciences announced positive interim results from its Phase 1b PRECISE-AD trial of PMN310, an experimental Alzheimer's disease treatment. The drug showed a favorable safety profile with no ARIA-E cases across all genotypes including high-risk APOE4 carriers, and demonstrated early biomarker movement consistent with target engagement. Full 12-month topline results are expected in Q1 2027.

GlobeNewswire Inc.

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

ProMIS Neurosciences announced positive Phase 1a trial results showing PMN310, its lead Alzheimer's drug candidate, achieved dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid. The company demonstrated target engagement in healthy volunteers and plans to present six-month blinded interim data from its Phase 1b PRECISE-AD trial in the coming weeks, with top-line results expected in early Q1 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 28, 20251-for-25reverse split